文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

异源与同源COVID-19疫苗方案对奥密克戎变异株发病率影响的比较:意大利南部一项真实世界回顾性队列研究

Performance comparison between heterologous and homologous COVID19 vaccine schedules on Omicron variant incidence: A real-world retrospective cohort study in Southern Italy.
PubMed 文献 · Vaccine · 2023-08-09

该回顾性队列研究利用意大利南部普利亚大区感染区域信息系统和疫苗登记数据,纳入2021年9月至2022年8月间在莱切省接种加强针的469,069名成年人,比较14种COVID-19疫苗方案在预防奥密克戎SARS-CoV-2感染方面的表现。结果显示不同方案标准化累计发病率差异大,最高为AZ-AZ-BNT(34.7%),最低为MOD-MOD-BNT(18.9%),部分异源方案优于同源方案;MOD-MOD-BNT方案风险最低,共同比值比为0.661(95%CI 0.620-0.704)。作者认为异源接种方案可能更有效预防奥密克戎感染。

要点

  • 不同COVID-19疫苗方案预防奥密克戎感染的标准化发病率差异大,最高AZ-AZ-BNT为34.7%,最低MOD-MOD-BNT为18.9%。
  • 部分异源方案感染风险显著低于同源方案,表现最佳的MOD-MOD-BNT共同OR为0.661(95%CI 0.620-0.704)。
  • 作者认为异源接种方案可能更有效预防奥密克戎感染,疫苗产品而非平台可能参与不同保护效果。

核心结论

  • 作者认为异源接种方案可能比同源方案更有效预防奥密克戎SARS-CoV-2感染,并提示疫苗产品而非平台参与异源接种提供的不同保护。

研究设计与样本

  • 回顾性队列研究,利用感染区域信息系统和普利亚大区疫苗登记数据,纳入2021年9月至2022年8月在意大利南部莱切省接种加强针的成年人,共469,069名受试者,涉及14种COVID-19疫苗方案。

主要发现

  • 加强针后SARS-CoV-2感染的标准化累计发病率在不同疫苗方案间差异大,最高为AZ-AZ-BNT(34.7%),最低为MOD-MOD-BNT(18.9%)。
  • 部分异源方案感染风险显著低于同源方案,表现最佳的MOD-MOD-BNT共同比值比为0.661(95%CI 0.620-0.704)。

关键数值与推荐

  • 采用Cochran-Mantel-Haenszel检验比较异源与同源方案亚组间感染风险。
  • 标准化累计发病率最高为AZ-AZ-BNT(34.7%),最低为MOD-MOD-BNT(18.9%)。
  • MOD-MOD-BNT方案共同比值比为0.661(95%CI 0.620-0.704)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As the COVID19 pandemic progresses, there is an increasing need to evaluate the performance of vaccine strategies. This study investigated the vaccine schedule performance of heterologous vaccination compared to homologous vaccination in preventing Omicron SARS-CoV2 infection in the adult population. This retrospective cohort study utilized data from the Infections Regional Information System and the Apulia Regional Vaccine Registry to identify individuals who received a booster dose of one of 14 different COVID19 vaccination schedules between September 2021 and August 2022 in the province of Lecce, Southern Italy. The standardized cumulative incidence of SARS-CoV2 infection after the booster dose was assessed and the risk of infection between subgroups of heterologous and homologous vaccination schedules was compared using the Cochran-Mantel-Haenszel test. A total of 469,069 subjects were included in the study. The standardized incidence of SARS-CoV2 infection varied greatly among different vaccine schedules, with the highest and lowest being AZ-AZ-BNT (34.7 %) and MOD-MOD-BNT (18.9 %), respectively, and some heterologous schedules performing better than homologous ones. The risk of SARS-CoV2 infection was significantly lower in individuals who received specific heterologous vaccination schedules compared to homologous vaccination schedules, the best performing being MOD-MOD-BNT with a common odd ratio of 0.661 (IC. 95 % [0.620-0.704]). This study provides evidence that heterologous vaccination schedules may be more effective in preventing Omicron SARS-CoV2 infection compared to homologous vaccination schedules, highlighting how the vaccine product, rather than the platform, is involved in the different protection provided by heterologous vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Baglivo F, Magrì M, De Angelis L, et al. Performance comparison between heterologous and homologous COVID19 vaccine schedules on Omicron variant incidence: A real-world retrospective cohort study in Southern Italy. Vaccine. 2023. PMID: 37567798. doi:10.1016/j.vaccine.2023.07.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。